Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medical Specialties (22)
- Psychiatry (5)
- Hematology (3)
- Oncology (3)
- Cardiology (2)
-
- Gastroenterology (2)
- Medical Molecular Biology (2)
- Medical Sciences (2)
- Neurology (2)
- Clinical Epidemiology (1)
- Community Health and Preventive Medicine (1)
- Emergency Medicine (1)
- Endocrinology, Diabetes, and Metabolism (1)
- Internal Medicine (1)
- Nephrology (1)
- Obstetrics and Gynecology (1)
- Ophthalmology (1)
- Pathology (1)
- Pediatrics (1)
- Public Health (1)
Articles 1 - 23 of 23
Full-Text Articles in Medicine and Health Sciences
Correction To: Safety Of Psychotropic Medications In People With Covid-19: Evidence Review And Practical Recommendations (Vol 18, 215, 2020), G. Ostuzzi, D. Papola, C. Gastaldon, G. Schoretsanitis, F. Bertolini, F. Amaddeo, A. Cuomo, R. Emsley, C. U. Correll, C. Barbui, +12 Additional Authors
Correction To: Safety Of Psychotropic Medications In People With Covid-19: Evidence Review And Practical Recommendations (Vol 18, 215, 2020), G. Ostuzzi, D. Papola, C. Gastaldon, G. Schoretsanitis, F. Bertolini, F. Amaddeo, A. Cuomo, R. Emsley, C. U. Correll, C. Barbui, +12 Additional Authors
Journal Articles
No abstract provided.
Significance Of Blood And Cerebrospinal Fluid Biomarkers For Alzheimer's Disease: Sensitivity, Specificity And Potential For Clinical Use, C. D'Abramo, L. D'Adamio, L. Giliberto
Significance Of Blood And Cerebrospinal Fluid Biomarkers For Alzheimer's Disease: Sensitivity, Specificity And Potential For Clinical Use, C. D'Abramo, L. D'Adamio, L. Giliberto
Journal Articles
No abstract provided.
Effect Of Depression Screening After Acute Coronary Syndromes On Quality Of Life The Codiacs-Qol Randomized Clinical Trial, I. M. Kronish, N. Moise, Y. K. Cheung, G. N. Clarke, R. J. Dolor, J. Duer-Hefele, K. L. Margolis, T. St Onge, F. Parsons, K. W. Davidson, +2 Additional Authors
Effect Of Depression Screening After Acute Coronary Syndromes On Quality Of Life The Codiacs-Qol Randomized Clinical Trial, I. M. Kronish, N. Moise, Y. K. Cheung, G. N. Clarke, R. J. Dolor, J. Duer-Hefele, K. L. Margolis, T. St Onge, F. Parsons, K. W. Davidson, +2 Additional Authors
Journal Articles
No abstract provided.
Polycystic Ovary Syndrome And Gender Identity, M. Liu, S. Murthi, L. Poretsky
Polycystic Ovary Syndrome And Gender Identity, M. Liu, S. Murthi, L. Poretsky
Journal Articles
No abstract provided.
Thrombotic Microangiopathy And Acute Kidney Injury Induced After Intravitreal Injection Of Vascular Endothelial Growth Factor Inhibitors Vegf Blockade-Related Tma After Intravitreal Use, R. M. Hanna, N. Tran, S. S. Patel, J. Hou, K. D. Jhaveri, R. Parikh, U. Selamet, L. Ghobry, V. Bijol, I. B. Kurtz, +6 Additional Authors
Thrombotic Microangiopathy And Acute Kidney Injury Induced After Intravitreal Injection Of Vascular Endothelial Growth Factor Inhibitors Vegf Blockade-Related Tma After Intravitreal Use, R. M. Hanna, N. Tran, S. S. Patel, J. Hou, K. D. Jhaveri, R. Parikh, U. Selamet, L. Ghobry, V. Bijol, I. B. Kurtz, +6 Additional Authors
Journal Articles
No abstract provided.
Reevaluation Of The Us Pathologist Workforce Size, S. J. Robboy, D. Gross, J. Y. Park, E. Kittrie, J. M. Crawford, R. L. Johnson, M. B. Cohen, D. S. Karcher, R. D. Hoffman, W. S. Black-Schaffer, +1 Additional Author
Reevaluation Of The Us Pathologist Workforce Size, S. J. Robboy, D. Gross, J. Y. Park, E. Kittrie, J. M. Crawford, R. L. Johnson, M. B. Cohen, D. S. Karcher, R. D. Hoffman, W. S. Black-Schaffer, +1 Additional Author
Journal Articles
No abstract provided.
Racial Disparity In Pregnancy Risks And Complications In The Us: Temporal Changes During 2007-2018, E. Bornstein, Y. Eliner, F. A. Chervenak, A. Grunebaum
Racial Disparity In Pregnancy Risks And Complications In The Us: Temporal Changes During 2007-2018, E. Bornstein, Y. Eliner, F. A. Chervenak, A. Grunebaum
Journal Articles
No abstract provided.
Hydroxyurea For Children With Sickle Cell Anemia In Sub-Saharan Africa, L. Tshilolo, G. Tomlinson, T. N. Williams, B. Santos, P. Olupot-Olupot, A. Lane, B. Aygun, S. E. Stuber, K. Mcelhinney, +59 Additional Authors
Hydroxyurea For Children With Sickle Cell Anemia In Sub-Saharan Africa, L. Tshilolo, G. Tomlinson, T. N. Williams, B. Santos, P. Olupot-Olupot, A. Lane, B. Aygun, S. E. Stuber, K. Mcelhinney, +59 Additional Authors
Journal Articles
No abstract provided.
The Comb Sign In Crohn's Ileocolitis, N. Adlakha, A. Swaminath
The Comb Sign In Crohn's Ileocolitis, N. Adlakha, A. Swaminath
Journal Articles
No abstract provided.
Racial And Ethnic Disparities In Diagnosis Of Chronic Medical Conditions In The Usa, E. J. Kim, T. Kim, J. Conigliaro, J. M. Liebschutz, M. K. Paasche-Orlow, A. D. Hanchate
Racial And Ethnic Disparities In Diagnosis Of Chronic Medical Conditions In The Usa, E. J. Kim, T. Kim, J. Conigliaro, J. M. Liebschutz, M. K. Paasche-Orlow, A. D. Hanchate
Journal Articles
No abstract provided.
Declining Medicaid Fees And Primary Care Appointment Availability For New Medicaid Patients, M. Candon, S. Zuckerman, D. Wissoker, B. Saloner, G. M. Kenney, K. Rhodes, D. Polsky
Declining Medicaid Fees And Primary Care Appointment Availability For New Medicaid Patients, M. Candon, S. Zuckerman, D. Wissoker, B. Saloner, G. M. Kenney, K. Rhodes, D. Polsky
Journal Articles
No abstract provided.
Hereditary Diffuse Gastric Cancer: One Family's Story, H. M. Zylberberg, K. Sultan, S. Rubin
Hereditary Diffuse Gastric Cancer: One Family's Story, H. M. Zylberberg, K. Sultan, S. Rubin
Journal Articles
No abstract provided.
A Collaborative, Network-Based Approach To Advance Women's Depression Research In The United States: Preliminary Findings, H. A. Flynn, C. Spino, C. Guille, K. M. Deligiannidis, P. Maki, J. Jahnke, K. L. Rosenblum, C. N. Epperson, S. J. Weiss
A Collaborative, Network-Based Approach To Advance Women's Depression Research In The United States: Preliminary Findings, H. A. Flynn, C. Spino, C. Guille, K. M. Deligiannidis, P. Maki, J. Jahnke, K. L. Rosenblum, C. N. Epperson, S. J. Weiss
Journal Articles
No abstract provided.
The Role Of Objectively Measured, Altered Physical Activity Patterns For Body Mass Index Change During Inpatient Treatment In Female Patients With Anorexia Nervosa, C. S. Lehmann, T. Hofmann, U. Elbelt, M. Rose, C. U. Correll, A. Stengel, V. Haas
The Role Of Objectively Measured, Altered Physical Activity Patterns For Body Mass Index Change During Inpatient Treatment In Female Patients With Anorexia Nervosa, C. S. Lehmann, T. Hofmann, U. Elbelt, M. Rose, C. U. Correll, A. Stengel, V. Haas
Journal Articles
No abstract provided.
Medical Management With Or Without Interventional Therapy For Unruptured Brain Arteriovenous Malformations (Aruba): A Multicentre, Non-Blinded, Randomised Trial, J. P. Mohr, M. K. Parides, C. Stapf, E. Moquete, C. S. Moy, J. R. Overbey, R. A. S. Salman, E. Vicaut, R. Libman, Aruba Investigators Int, +12 Additional Authors
Medical Management With Or Without Interventional Therapy For Unruptured Brain Arteriovenous Malformations (Aruba): A Multicentre, Non-Blinded, Randomised Trial, J. P. Mohr, M. K. Parides, C. Stapf, E. Moquete, C. S. Moy, J. R. Overbey, R. A. S. Salman, E. Vicaut, R. Libman, Aruba Investigators Int, +12 Additional Authors
Journal Articles
Background The clinical benefit of preventive eradication of unruptured brain arteriovenous malformations remains uncertain. A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) aims to compare the risk of death and symptomatic stroke in patients with an unruptured brain arteriovenous malformation who are allocated to either medical management alone or medical management with interventional therapy. Methods Adult patients (>= 18 years) with an unruptured brain arteriovenous malformation were enrolled into this trial at 39 clinical sites in nine countries. Patients were randomised (by web-based system, in a 1: 1 ratio, with random permuted block design [block size 2, 4, …
Long-Term Exposure To Traffic-Related Air Pollution And Progression Of Carotid Artery Atherosclerosis: A Prospective Cohort Study, W. Q. Gan, R. W. Allen, M. Brauer, H. W. Davies, G. B. J. Mancini, S. A. Lear
Long-Term Exposure To Traffic-Related Air Pollution And Progression Of Carotid Artery Atherosclerosis: A Prospective Cohort Study, W. Q. Gan, R. W. Allen, M. Brauer, H. W. Davies, G. B. J. Mancini, S. A. Lear
Journal Articles
Objectives Epidemiological studies have demonstrated associations between long-term exposure to traffic-related air pollution and coronary heart disease (CHD). Atherosclerosis is the principal pathological process responsible for CHD events, but effects of traffic-related air pollution on progression of atherosclerosis are not clear. This study aimed to investigate associations between long-term exposure to traffic-related air pollution and progression of carotid artery atherosclerosis. Setting Healthy volunteers in metropolitan Vancouver, Canada. Participants and outcome measures 509 participants aged 30-65years were recruited and followed for approximately 5years. At baseline and end of follow-up, participants underwent carotid artery ultrasound examinations to assess atherosclerosis severity, including carotid …
Glycated Hemoglobin Measurement And Prediction Of Cardiovascular Disease, E. Di Angelantonio, P. Gao, H. Khan, N. Wald, S. J. L. Bakker, P. H. Whincup, J. Kauhanen, J. T. Salonen, R. Dankner, J. Danesh, +66 Additional Authors
Glycated Hemoglobin Measurement And Prediction Of Cardiovascular Disease, E. Di Angelantonio, P. Gao, H. Khan, N. Wald, S. J. L. Bakker, P. H. Whincup, J. Kauhanen, J. T. Salonen, R. Dankner, J. Danesh, +66 Additional Authors
Journal Articles
IMPORTANCE The value of measuring levels of glycated hemoglobin (HbA(1c)) for the prediction of first cardiovascular events is uncertain. OBJECTIVE To determine whether adding information on HbA(1c) values to conventional cardiovascular risk factors is associated with improvement in prediction of cardiovascular disease (CVD) risk. DESIGN, SETTING, AND PARTICIPANTS Analysis of individual-participant data available from 73 prospective studies involving 294 998 participants without a known history of diabetes mellitus or CVD at the baseline assessment. MAIN OUTCOMES AND MEASURES Measures of risk discrimination for CVD outcomes (eg, C-index) and reclassification (eg, net reclassification improvement) of participants across predicted 10-year risk categories …
Twelve Or 30 Months Of Dual Antiplatelet Therapy After Drug-Eluting Stents, L. Mauri, D. J. Kereiakes, R. W. Yeh, P. Driscoll-Shempp, K. N. Garratt, D. P. Lee, T. K. Pow, P. V. Lee, M. J. Rinaldi, J. M. Massaro, +12 Additional Authors
Twelve Or 30 Months Of Dual Antiplatelet Therapy After Drug-Eluting Stents, L. Mauri, D. J. Kereiakes, R. W. Yeh, P. Driscoll-Shempp, K. N. Garratt, D. P. Lee, T. K. Pow, P. V. Lee, M. J. Rinaldi, J. M. Massaro, +12 Additional Authors
Journal Articles
BACKGROUND Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial …
Does A Glp-1 Receptor Agonist Change Glucose Tolerance In Patients Treated With Antipsychotic Medications? Design Of A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial, J. R. Larsen, L. Vedtofte, J. J. Holst, P. Oturai, A. Kjaer, Christoph Correll, T. Vilsboll, A. Fink-Jensen
Does A Glp-1 Receptor Agonist Change Glucose Tolerance In Patients Treated With Antipsychotic Medications? Design Of A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial, J. R. Larsen, L. Vedtofte, J. J. Holst, P. Oturai, A. Kjaer, Christoph Correll, T. Vilsboll, A. Fink-Jensen
Journal Articles
Background Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances. Additionally, patients with schizophrenia-spectrum disorders not infrequently consume alcohol. Glucagon-like peptide-1 (GLP-1) has shown to improve glycaemic control and reduce alcohol intake among patients with type 2 diabetes. Objectives To investigate whether the beneficial effects of GLP-1 analogues on glycaemic control and alcohol intake, in patients with type 2 diabetes, can be extended to a population of pre-diabetic psychiatric patients receiving antipsychotic treatment. Methods and analysis Trial …
Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen
Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen
Journal Articles
Introduction: Antipsychotic treatment in early-onset schizophrenia (EOS) lacks a rich evidence base, and efforts to rank different drugs concerning their efficacy have not proven any particular drug superior. In contrast to the literature regarding adult-onset schizophrenia (AOS), comparative effectiveness studies in children and adolescents are limited in number and size, and only a few meta-analyses based on conventional methodologies have been conducted. Methods and analyses: We will conduct a network meta-analysis of all randomised controlled trials (RCTs) that evaluate antipsychotic therapies for EOS to determine which compounds are efficacious, and to determine the relative efficacy and safety of these treatments …
Resistance Mechanisms For The Bruton's Tyrosine Kinase Inhibitor Ibrutinib, J. A. Woyach, R. R. Furman, T. M. Liu, H. G. Ozer, M. Zapatka, A. S. Ruppert, L. Xue, D. H. H. Li, J. C. Barrientos, J. C. Byrd, +15 Additional Authors
Resistance Mechanisms For The Bruton's Tyrosine Kinase Inhibitor Ibrutinib, J. A. Woyach, R. R. Furman, T. M. Liu, H. G. Ozer, M. Zapatka, A. S. Ruppert, L. Xue, D. H. H. Li, J. C. Barrientos, J. C. Byrd, +15 Additional Authors
Journal Articles
BACKGROUND Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized. Although only a small proportion of patients have had a relapse during ibrutinib therapy, an understanding of resistance mechanisms is important. We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance. METHODS We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy. We then performed functional analysis of identified mutations. …
Idelalisib And Rituximab In Relapsed Chronic Lymphocytic Leukemia, R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, S. M. O'Brien, +17 Additional Authors
Idelalisib And Rituximab In Relapsed Chronic Lymphocytic Leukemia, R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, S. M. O'Brien, +17 Additional Authors
Journal Articles
BackgroundPatients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population. MethodsIn this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in combination with rituximab versus rituximab plus placebo. We randomly assigned 220 patients with decreased renal function, previous therapy-induced myelosuppression, or major coexisting illnesses to receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily. …
Ibrutinib Versus Ofatumumab In Previously Treated Chronic Lymphoid Leukemia, J. C. Byrd, J. R. Brown, S. O'Brien, J. C. Barrientos, N. E. Kay, N. M. Reddy, S. Coutre, C. S. Tam, S. P. Mulligan, P. Hillmen, +25 Additional Authors
Ibrutinib Versus Ofatumumab In Previously Treated Chronic Lymphoid Leukemia, J. C. Byrd, J. R. Brown, S. O'Brien, J. C. Barrientos, N. E. Kay, N. M. Reddy, S. Coutre, C. S. Tam, S. P. Mulligan, P. Hillmen, +25 Additional Authors
Journal Articles
Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome. Methods In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response …